Milder chemo before transplant shows promise for older blood cancer patients

NCT ID NCT05436561

Recruiting now Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Mar 23, 2026 · Last updated May 06, 2026 · Updated 2 times

Summary

This study tests a reduced-intensity chemotherapy combination (fludarabine, busulfan, and melphalan) given before a stem cell transplant in people aged 55 and older with certain blood cancers (AML, MDS, CMML). The goal is to see if this gentler approach can help patients stay free of cancer for longer. About 61 participants will receive the treatment and be followed for survival and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DISEASE-FREE SURVIVAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Blood & Marrow Transplantation Center, RuiJin Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shanghai No 6 Hospital
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DISEASE-FREE SURVIVAL